Virpax appoints board member Katharyn Field as Vice President and principal executive officer

Virpax Pharmaceuticals, Inc.

Katharyn Field appointed VP and principal executive officer effective Sept. 27, 2024.
Field will continue to serve as a member of the Board of Directors.
Company is an emerging growth company; no prior CEO departure noted.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Katharyn Field

Vice President (principal executive officer)

Virpax Pharmaceuticals, Inc.

Effective: 2024-09-27
Filed: October 3, 2024, 7:59 PM ET

On September 27, 2024, the Board of Directors (the “Board”) of Virpax Pharmaceuticals, Inc. (the “Company”) appointed Katharyn Field, a member of the Board, to also serve as a Vice President (principal executive officer) of the Company, effective immediately.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Katharyn Field was appointed as Vice President (principal executive officer) at Virpax Pharmaceuticals, Inc..

Action: appointed
Role: Vice President (principal executive officer)

Exact text from the filing

On September 27, 2024, the Board of Directors (the “Board”) of Virpax Pharmaceuticals, Inc. (the “Company”) appointed Katharyn Field, a member of the Board, to also serve as a Vice President (principal executive officer) of the Company, effective immediately.

View on SEC.gov

Source: SEC EDGAR

accession 0001731122-24-001539

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.